Table 1 Baseline characteristics of the HNSC CCRT derivation cohort (n = 120).

Age group (years)

0.527

 <45

8 (6.7%)

3 (4.5%)

5 (9.4%)

 >65

35 (29.2%)

21 (31.3%)

14 (26.4%)

 45–64

77 (64.2%)

43 (64.2%)

34 (64.2%)

Sex

0.731

 Female

8 (6.7%)

4 (6.0%)

4 (7.5%)

 Male

112 (93.3%)

63 (94.0%)

49 (92.5%)

Location

0.497

 HPC

13 (10.8%)

6 (9.0%)

7 (13.2%)

 LC

4 (3.3%)

1 (1.5%)

3 (5.7%)

 OC

79 (65.8%)

45 (67.2%)

34 (64.2%)

 OPC

24 (20.0%)

15 (22.4%)

9 (17.0%)

Grade

0.858

 Grade 1

33 (28.2%)

19 (29.7%)

14 (26.4%)

 Grade 2

62 (53.0%)

34 (53.1%)

28 (52.8%)

 Grade 3

22 (18.8%)

11 (17.2%)

11 (20.8%)

 Missing

3

3

0

Margin

0.069

 Free

57 (76.0%)

24 (66.7%)

33 (84.6%)

 Not free

18 (24.0%)

12 (33.3%)

6 (15.4%)

 Missing

45

31

14

ENE

0.996

 No

39 (48.8%)

19 (48.7%)

20 (48.8%)

 Yes

41 (51.2%)

20 (51.3%)

21 (51.2%)

 Missing

40

28

12

LVI+

88 (73.3%)

50 (74.6%)

38 (71.7%)

0.719

PNI+

32 (26.7%)

17 (25.4%)

15 (28.3%)

0.290

Stage

0.550

 Stage I

4 (3.5%)

1 (1.6%)

3 (5.9%)

 Stage II

5 (4.4%)

2 (3.2%)

3 (5.9%)

 Stage III

12 (10.5%)

7 (11.1%)

5 (9.8%)

 Stage IV

99 (82.5%)

57 (85.1%)

42 (79.2%)

Surgery

84 (70.0%)

41 (61.2%)

43 (81.1%)

0.018

Induction

17 (14.2%)

12 (17.9%)

5 (9.4%)

0.186

CCRT response

<0.001

 CR

55 (45.8%)

41 (61.2%)

14 (26.4%)

 PR

27 (22.5%)

17 (25.4%)

10 (18.9%)

 SD

7 (5.8%)

5 (7.5%)

2 (3.8%)

 PD

31 (25.8%)

4 (6.0%)

27 (50.9%)

TMB, mut/Mb

3.8 (0.0–25.2)

3.8 (0.0–15.1)

3.8 (0.0–25.2)

0.680

 <10

111 (92.5%)

60 (89.6%)

51 (96.2%)

0.296

 ≥10

9 (7.5%)

7 (10.4%)

2 (3.8%)

Overall survival

<0.001

 Died

27 (22.5%)

3 (4.5%)

24 (45.3%)

 Survived

93 (77.5%)

64 (95.5%)

29 (54.7%)